Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
115 studies found for:    IL7R
Show Display Options
Rank Status Study
1 Not yet recruiting Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
Condition: Autoimmune Diseases
Interventions: Drug: GSK2618960;   Drug: Placebo
2 Completed IL-7 Receptor Polymorphisms and Immune Recovery With HAART
Condition: HIV Infections
Intervention:
3 Terminated A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
4 Recruiting A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Biological: PF-06342674 0.25 mg/kg;   Biological: Placebo;   Biological: PF-06342674 1.5 mg/kg;   Biological: PF-06342674 6.0 mg/kg
5 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
6 Unknown  Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease
Conditions: End-stage Kidney Disease;   CD4 T Cells;   Central Memory T Cells;   Regulatory T Cells;   Uremic Toxins
Intervention: Device: Polyamide HD membrane
7 Completed Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
Condition: Hepatitis C
Intervention: Drug: Interleukin-7
8 Unknown  Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone
Condition: Hepatitis C
Intervention: Drug: Interleukin-7
9 Unknown  Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
Condition: Hepatitis C
Intervention: Drug: Interleukin-7
10 Unknown  Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients
Condition: Chronic Hepatitis B
Interventions: Drug: CYT107+GenHevac+entecavir or tenofovir;   Drug: CYT107+ entecavir or tenofovir
11 Terminated Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
Conditions: Kidney Cancer;   Melanoma (Skin)
Interventions: Biological: recombinant interleukin-7;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Terminated Study on Interleukin-7 (CYT107) in HIV Patients
Condition: HIV
Intervention: Biological: Interleukin-7
13 Active, not recruiting
Has Results
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Conditions: Neuroblastoma;   Sarcoma;   Rhabdomyosarcoma-Embryonal;   Rhabdomyosarcoma- Alveolar;   Neuroectodermal Tumors, Primitive, Peripheral
Interventions: Drug: Tumor Purged/CD25 Depleted Lymphocytes;   Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine;   Drug: rhIL-7;   Biological: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
14 Withdrawn Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: lopinavir;   Drug: ritonavir;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis
15 Completed Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
Condition: HIV-1 Infection
Interventions: Drug: ART Intensification;   Biological: Immunomodulation
16 Recruiting High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
Condition: Neuroblastoma
Interventions: Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan;   Drug: Melphalan
17 Completed
Has Results
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate );   Drug: Placebo
18 Not yet recruiting Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Conditions: Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Intervention: Biological: MVST
19 Unknown  Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
Conditions: Kidney Transplantation;   Kidney Diseases;   Kidney Failure
Interventions: Drug: Alemtuzumab;   Drug: Daclizumab
20 Completed
Has Results
Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults
Conditions: Influenza A Virus, H1N1 Subtype;   Influenza Infection
Interventions: Biological: GSK2340274A;   Biological: GSK2340273A;   Biological: Seasonal trivalent influenza vaccine (TIV);   Biological: Saline placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years